Eli Lilly and Company announced on Thursday that its revenue in the third quarter of fiscal 2023 amounted to $9.5 billion and climbed 37% year over year, exceeding estimates. Net loss came at $57.4 million while loss per share in the reported trimester clocked at $0.06. The full-year 2023 revenue guidance remained unchanged between $33.4 billion and $33.9 as reported in the previous earning report.
"Lilly had another strong quarter in Q3 as Mounjaro and Verzenio continued to gain momentum … Lilly executed on business development priorities in the third quarter, including multiple acquisitions that expand our already robust pipeline. We remain focused on growth and delivering new, innovative medicines that make life better for millions of patients around the globe," CEO David Ricks mentioned.
The company's shares fell 2.79% in premarket trading following the earnings announcement.
